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ash and GI Symptoms on Day 36A 44-year-old man with AML in CR2 had a matched unrelated donor PBSC transplant using busulfan and
cyclophosphamide conditioning. The patient and donor were CMV positive. GVHD prophylaxis was
tacrolimus/methotrexate.
At day 23, an erythematous rash on his upper back, shoulders, and ears was treated with topical triamcin-
olone cream and resolved. At day36 (Friday afternoon), he presents with 2 days of watery diarrhea (4 stools;
estimated 700 mL per day), nausea, and anorexia, and a new erythematous rash over his upper chest, back,
and arms. On physical exam, he is afebrile and has a rash. His abdomen is minimally tender without rebound.
Laboratories are notable for WBC 3400 (absolute neutrophil count 1900), platelets 36,000, creatinine 1.5,
total bilirubin 2.4, direct bilirubin 1.9, alkaline phosphatase 195 (nL <150); AST 44 (nL <50). Trough
tacrolimus level 10. CMV DNA PCR showed 850 copies (previously negative <500). He is taking tacrolimus
and fluconazole plus scheduled medications for depression, heartburn, hypertension, edema, and hypoka-
lemia. Skin and gastrointestinal (GI) biopsies are done.
What would you recommend next?
● No therapy until results of skin and GI biopsy are available.
● Start prednisone 2 mg/kg/day along with ganciclovir 5 mg/kg every 12 hours.
● Start ganciclovir 5 mg/kg every 12 hours. Add prednisone only if GI biopsy is positive for GVHD.
● Start prednisone 2 mg/kg/day. Add ganciclovir only if GI biopsy shows CMV.
C
sURTHER DEVELOPMENTS
After 8 days (day 44), his diarrhea (850 mL/day)
nd rash persist and are unchanged. The skin biopsy
hows GVHD. The GI biopsy results are still pend-
ng. His total bilirubin is 3.2, creatinine 1.8, repeat
MV DNA PCR is negative.
What would you recommend?
Continue initial treatment.
No change in therapy, order liver biopsy.
Add prednisone 2 mg/kg/day.
Add ATG (horse or rabbit).
Add mycophenolate mofetil.
Add sirolimus.
Add etanercept.
Add other GVHD therapy not listed.
EADER RESPONSES
In a recent issue of the ASBMT eNEWS, readers
ere presented with the above Clinical Challenge and
nvited to use an online poll to recommend a course of
reatment. The reader recommendations for therapy
ere: r44% Start prednisone 2 mg/kg/day along with
ganciclovir 5 mg/kg every 12 hours.
29% Start ganciclovir 5 mg/kg every 12 hours.
Add prednisone only if GI biopsy is positive
for GVHD.
24% Start prednisone 2 mg/kg/day. Add ganci-
clovir only if GI biopsy shows CMV.
3% No therapy until results of skin and GI
biopsy are available.
Further developments:
34% Add prednisone 2 mg/kg/day.
26% Add mycophenolate mofetil.
9% Add ATG (horse or rabbit).
9% Add etanercept.
9% Add other GVHD therapy not listed.
5% No change in therapy, order liver biopsy.
4% Continue initial treatment.
4% Add sirolimus.
OMMENTARY
This patient’s clinical presentation most strongly
uggests acute GVHD, possibly complicated by CMV
eactivation. Forty-four percent of respondents fa-
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D. Weiddorf1406ored concurrent treatment for CMV and GVHD,
hereas 29% would treat only for CMV and 24%
ould treat only for GVHD at this point. Given the
ew skin/gut/liver ﬁndings, the diagnosis of GVHD is
linically established, and treatment should not await
iopsy documentation. Prompt initiation of steroids is
arranted even when a patient has low stage multior-
an GVHD (skin stage 2, gut 1, liver 1; clinical grade
I or grade B using Consensus or IBMTR grading
chemas).
In addition, effective antiviral therapy should be
tarted in a patient with low level viremia, particularly
f steroids are started for GVHD. I favor treatment
ith ganciclovir over foscarnet or cidofovir, especially
n a patient with mildly compromised renal function
eceiving tacrolimus.
With undetectable CMV, persistence of the
VHD symptoms after 8 days is a usual indication for
dded therapy. I would also review the patient’s med-
cations and workup thus far (review/repeat earlier
iopsies; consider liver biopsy) and consider alternate
iagnoses that could explain why the patient is not
esponding to GVHD treatment. For example, I
ould consider other diagnoses such as a drug rash, C.
ifﬁcile, withdrawal of constipating drugs like opiates,
rug-induced diarrhea from antacids, magnesium, or
tool softeners or drug-induced cholestasis from ﬂu-
onazole, voriconazole, or TMP-sulfa could be con-
ounding or exaggerating the signs of GVHD.
Second choice therapy for steroid-resistant acute
VHD is not standardized, and the poll reﬂects the
ncertainty in the ﬁeld. Only prednisone (for those
4% not giving it initially) or mycophenolate motetil
chosen by 26%) received substantial enthusiasm. A
ew chose ATG, sirolimus, etanercept, or other ther-
py. For uncertain reasons, nearly 9% of respondents
id not add additional therapy despite clear persis-
ence of GVHD after 8 days of high dose steroids. I
ould not recommend this approach, as early recog-
ition of steroid-resistant GVHD and addition of a
econd agent is most likely to result in control of
VHD, even if the optimal therapy is still undeﬁned.n the absence of an appropriate clinical trial, addition
f any of these agents is reasonable.
aniel Weisdorf
niversity of Minnesota
inneapolis, Minnesota
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